Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Cancer Treatment Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 1.5% during the forecast period.
This report presents the market size and development trends by detailing the Cancer Treatment Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Cancer Treatment Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Cancer Treatment Drugs industry and will help you to build a panoramic view of the industrial development.
Cancer Treatment Drugs Market, By Type:
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Cancer Treatment Drugs Market, By Application:
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
Some of the leading players are as follows:
Eisai
Sanofi
Bayer
Celgene
Amgen
Astellas
Kyowa Hakko Kirin
Teva
Johnson & Johnson
AbbVie
Bristol-Myers Squibb
AstraZeneca
Pfizer
Biogen Idec
Otsuka
Roche
Novartis
Gilead Sciences
Eli Lilly
Merck KGaA
Ipsen
Takeda
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Cancer Treatment Drugs Market: Technology Type Analysis
-
4.1 Cancer Treatment Drugs Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Cancer Treatment Drugs Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Chemotherapy
4.3.2 Targeted Therapy
4.3.3 Immunotherapy (Biologic Therapy)
4.3.4 Hormonal Therapy
4.3.5 Others
5 Cancer Treatment Drugs Market: Product Analysis
-
5.1 Cancer Treatment Drugs Product Market Share Analysis, 2018 & 2026
-
5.2 Cancer Treatment Drugs Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Cancer Treatment Drugs Market: Application Analysis
-
6.1 Cancer Treatment Drugs Application Market Share Analysis, 2018 & 2026
-
6.2 Cancer Treatment Drugs Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Blood Cancer
6.3.2 Breast Cancer
6.3.3 Gastrointestinal Cancer
6.3.4 Prostate Cancer
6.3.5 Respiratory/Lung Cancer
6.3.6 Other Cancers
7 Cancer Treatment Drugs Market: Regional Analysis
-
7.1 Cancer Treatment Drugs Regional Market Share Analysis, 2018 & 2026
-
7.2 Cancer Treatment Drugs Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Eisai
9.1.1 Eisai Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Sanofi
9.2.1 Sanofi Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 Bayer
9.3.1 Bayer Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Celgene
9.4.1 Celgene Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Amgen
9.5.1 Amgen Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Astellas
9.6.1 Astellas Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Kyowa Hakko Kirin
9.7.1 Kyowa Hakko Kirin Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 Teva
9.8.1 Teva Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 Johnson & Johnson
9.9.1 Johnson & Johnson Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 AbbVie
9.10.1 AbbVie Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 Bristol-Myers Squibb
9.11.1 Bristol-Myers Squibb Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 AstraZeneca
9.12.1 AstraZeneca Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 Pfizer
9.13.1 Pfizer Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Biogen Idec
9.14.1 Biogen Idec Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Otsuka
9.15.1 Otsuka Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Roche
9.16.1 Roche Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
9.17 Novartis
9.17.1 Novartis Company overview
9.17.2 Financial performance
9.17.3 Product benchmarking
9.17.4 Strategic initiatives
9.17.5 SWOT analysis
9.18 Gilead Sciences
9.18.1 Gilead Sciences Company overview
9.18.2 Financial performance
9.18.3 Product benchmarking
9.18.4 Strategic initiatives
9.18.5 SWOT analysis
9.19 Eli Lilly
9.19.1 Eli Lilly Company overview
9.19.2 Financial performance
9.19.3 Product benchmarking
9.19.4 Strategic initiatives
9.19.5 SWOT analysis
9.20 Merck KGaA
9.20.1 Merck KGaA Company overview
9.20.2 Financial performance
9.20.3 Product benchmarking
9.20.4 Strategic initiatives
9.20.5 SWOT analysis
9.21 Ipsen
9.21.1 Ipsen Company overview
9.21.2 Financial performance
9.21.3 Product benchmarking
9.21.4 Strategic initiatives
9.21.5 SWOT analysis
9.22 Takeda
9.22.1 Takeda Company overview
9.22.2 Financial performance
9.22.3 Product benchmarking
9.22.4 Strategic initiatives
9.22.5 SWOT analysis
The List of Tables and Figures (Totals 108 Figures and 137 Tables)
Figure Chemotherapy Cancer Treatment Drugs market, 2015 - 2026 (USD Million)
Figure Targeted Therapy Cancer Treatment Drugs market, 2015 - 2026 (USD Million)
Figure Immunotherapy (Biologic Therapy) Cancer Treatment Drugs market, 2015 - 2026 (USD Million)
Figure Hormonal Therapy Cancer Treatment Drugs market, 2015 - 2026 (USD Million)
Figure Others Cancer Treatment Drugs market, 2015 - 2026 (USD Million)
Figure Blood Cancer market, 2015 - 2026 (USD Million)
Figure Breast Cancer market, 2015 - 2026 (USD Million)
Figure Gastrointestinal Cancer market, 2015 - 2026 (USD Million)
Figure Prostate Cancer market, 2015 - 2026 (USD Million)
Figure Respiratory/Lung Cancer market, 2015 - 2026 (USD Million)
Figure Other Cancers market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Cancer Treatment Drugs market, by country, 2015 - 2026 (USD Million)
-
Table North America Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table North America Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table North America Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Canada Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Canada Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Europe Cancer Treatment Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Europe Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Europe Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Europe Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Germany Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Germany Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table France Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table France Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Italy Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Italy Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Spain Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Spain Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Treatment Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table China Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table China Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Japan Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Japan Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table India Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table India Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Treatment Drugs market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table MEA Cancer Treatment Drugs market, by country, 2015 - 2026 (USD Million)
-
Table MEA Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table MEA Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table MEA Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Cancer Treatment Drugs market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Treatment Drugs market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Cancer Treatment Drugs market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Eisai Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sanofi Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bayer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Celgene Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Amgen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Astellas Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Kyowa Hakko Kirin Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Teva Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AbbVie Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Bristol-Myers Squibb Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Pfizer Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Biogen Idec Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Otsuka Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Roche Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Novartis Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Gilead Sciences Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Eli Lilly Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Merck KGaA Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Ipsen Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Takeda Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
